Accepted for Publication: April 14, 2021.
Published Online: June 17, 2021. doi:10.1001/jamaoncol.2021.1799
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Thompson MA et al. JAMA Oncology.
Corresponding Author: Jeremy L. Warner, MD, MS, Division of Hematology/Oncology, Vanderbilt University, 2220 Pierce Ave, 777 PRB, Nashville, TN 37232 (jeremy.warner@vumc.org).
Author Contributions: Dr Warner had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Thompson and Henderson contributed equally. Drs D. P. Shah and Warner contributed equally
Concept and design: Thompson, Henderson, Rubinstein, Joyner, Choueiri, Xie, D. P. Shah, Warner.
Acquisition, analysis, or interpretation of data: Thompson, Henderson, P. Shah, Rubinstein, Choueiri, Flora, Griffiths, Gulati, Hwang, Koshkin, Papadopoulos, Robilotti, Su, Wulff-Burchfield, Xie, Yu, Mishra, Senefeld, D. P. Shah, Warner.
Drafting of the manuscript: Thompson, Henderson, P. Shah, Rubinstein, Joyner, Griffiths, Xie, Yu, D. P. Shah, Warner.
Critical revision of the manuscript for important intellectual content: Thompson, Henderson, Rubinstein, Choueiri, Flora, Griffiths, Gulati, Hwang, Koshkin, Papadopoulos, Robilotti, Su, Wulff-Burchfield, Xie, Yu, Mishra, Senefeld, D. P. Shah, Warner.
Statistical analysis: P. Shah, D. P. Shah.
Obtained funding: Henderson, Warner.
Administrative, technical, or material support: Thompson, Joyner, Choueiri, Flora, Griffiths, Hwang, Koshkin, Wulff-Burchfield, Yu, Mishra.
Supervision: Thompson, Henderson, Choueiri, Senefeld, D. P. Shah, Warner.
Conflict of Interest Disclosures: Dr Thompson reported receiving personal fees from Adaptive, BMS, Elsevier, Epizyme, Takeda, and AIM Specialty Health, royalties from UpToDate, personal fees from GRAIL/Illumina, and nonfinancial support (travel) from Syapse outside the submitted work. Dr Henderson reported receiving personal fees from Immunome outside the submitted work. Dr P. Shah reported receiving grants from the Biomedical Advanced Research and Development Authority during the conduct of the study. Dr Choueiri reported receiving nonfinancial support from the COVID-19 and Cancer Consortium, the European Society of Medical Oncology COVID-19 Registry for Patients With Cancer, and the COVID-19 and Cancer Outcomes Study during the conduct of the study and receiving honoraria from Pfizer, Exelixis, BMS, Merck, Roche/Genentech, Novartis, and Lilly and royalties for UpToDate outside the submitted work. Dr Griffiths reported receiving personal fees from Takeda Oncology, AbbVie, Novartis Pharmaceuticals, Celgene/BMS, Alexion Pharmaceuticals, and Boston Biomedical, nonfinancial support from Appelis Pharmaceuticals, and grants from Genentech outside the submitted work. Dr Hwang reported receiving grants from Merck, Exelixis, Bayer, AstraZeneca, Genentech, Dendreon, and Bausch, personal fees from Sanofi/Genzyme, Exelixis, Bristol Myers Squibb, Astellas, Medivation, Bayer, and Janssen Scientific, and owning stock in Johnson and Johnson outside the submitted work. Dr Koshkin reported receiving personal fees from AstraZeneca, Clovis, Janssen, Pfizer, EMD Serono, Seattle Genetics/Astellas, and Dendreon and grants from Endocyte, Nektar, Clovis, Taiho, and Janssen outside the submitted work. Dr Wulff-Burchfield reported receiving personal fees from Exelixis, BMS Consulting, and Pfizer Global and having a family member with stock ownership in Immunomedics and Nektar outside the submitted work. Dr Mishra reported receiving grants from the National Cancer Institute during the conduct of the study. Dr Senefeld reported having a contract with the Biomedical Advanced Research and Development Authority during the conduct of the study. Dr D. P. Shah reported receiving grants from the Biomedical Advanced Research and Development Authority, American Cancer Society, and Hope Foundation for Cancer Research during the conduct of the study. Dr Warner reported receiving grants from the National Cancer Institute during the conduct of the study, nonfinancial support from HemOnc.org LLC, and personal fees from Westat and IBM Watson Oncology outside the submitted work. No other disclosures were reported.
Funding/Support: This project has been funded in whole or in part with federal funds from the US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority under contract 75A50120C00096 (Drs Joyner, P. Shah, and D. P. Shah); National Cancer Institute grants P30 CA008748 (Drs Robilloti and Papadopolous), P30 CA046592 (Dr Su), P30 CA054174 (Drs P. Shah and D. P. Shah), P30 CA068485 (Drs Warner and Mishra), T32 CA236621 (Dr Su), and U01 CA231840 (Dr Warner); National Center for Advancing Translational Sciences grant UL1 TR002377 (Dr Joyner); Schwab Charitable Fund (Eric E. Schmidt, Wendy Schmidt, donors) (Dr Joyner); United Health Group (Dr Joyner); National Basketball Association (Dr Joyner); Millennium Pharmaceuticals (Dr Joyner); Octapharma USA Inc (Dr Joyner); grant MRSG-16-152-01-CCE from the American Cancer Society and Hope Foundation for Cancer Research (Dr. P. Shah); the Longer Life Foundation: A RGA/Washington University Partnership (Dr Henderson); and the Mayo Clinic (Drs Joyner and Senefeld). REDCap is developed and supported by the Vanderbilt Institute for Clinical and Translational Research under grant UL1 TR000445 from National Center for Advancing Translational Sciences/National Institutes of Health.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: A complete list of members of the COVID-19 and Cancer Consortium at sites contributing to this analysis appears in Supplement 2.
Disclaimer: The views and opinions expressed in this publication are those of the authors and do not reflect the official policy or position of the US Department of Health and Human services and its agencies, including the Biomedical Research and Development Authority and the US Food and Drug Administration, as well as any agency of the US government. Assumptions made within and interpretations from the analysis are not reflective of the position of any US government entity.
Additional Contributions: We thank all members of the CCC19 steering committee: Toni K. Choueiri, Narjust Duma, Dimitrios Farmakiotis, Petros Grivas, Gilberto de Lima Lopes Jr, Corrie A. Painter, Solange Peters, Brian I. Rini, Dimpy P. Shah, Michael A. Thompson, and Jeremy L. Warner, for their invaluable guidance of the CCC19 consortium. A list of individuals who made substantial contributions to data collection is provided in the eAppendix in Supplement 1; these contributions were uncompensated.
7.Kow
CS , Hasan
SS . Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease.
Rheumatol Int. 2020;40(12):2117-2118. doi:
10.1007/s00296-020-04715-0 9.Joyner
MJ , Carter
RE , Senefeld
JW ,
et al Convalescent plasma antibody levels and the risk of death from Covid-19.
N Engl J Med. 2021;384(11):1015-1027. doi:
10.1056/NEJMoa2031893 12.Senefeld
JW , Klassen
SA , Ford
SK ,
et al Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency.
medRxiv. Published online November 10, 2020:2020.11.08.20224790. doi:
10.1101/2020.11.08.20224790Google Scholar 13.COVID-19 and Cancer Consortium. A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance.
Cancer Cell. 2020;38(6):761-766. doi:
10.1016/j.ccell.2020.10.022
PubMedCrossref 15.Austin
PC . Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.
Pharm Stat. 2011;10(2):150-161. doi:
10.1002/pst.433
PubMedGoogle ScholarCrossref 17.Algwaiz
G , Aljurf
M , Koh
M ,
et al; WBMT and the CIBMTR Health Services and International Studies Committee. Real-world issues and potential solutions in hematopoietic cell transplantation during the COVID-19 pandemic: perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee.
Biol Blood Marrow Transplant. 2020;26(12):2181-2189. doi:
10.1016/j.bbmt.2020.07.021
PubMedGoogle ScholarCrossref 20.Thakkar
A , Pradhan
K , Jindal
S ,
et al Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy.
Nat Cancer. 2021;2:1-8. doi:
10.1038/s43018-021-00191-y 21.Ferrari
S , Caprioli
C , Weber
A , Rambaldi
A , Lussana
F . Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
Leuk Lymphoma. Published online January 18, 2021. doi:
10.1080/10428194.2021.1872070
PubMedGoogle Scholar 22.Tremblay
D , Seah
C , Schneider
T ,
et al; Mount Sinai Health System Convalescent Plasma Team. Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients.
Cancer Med. 2020;9(22):8571-8578. doi:
10.1002/cam4.3457
PubMedGoogle ScholarCrossref 25.Mair-Jenkins
J , Saavedra-Campos
M , Baillie
JK ,
et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.
J Infect Dis. 2015;211(1):80-90. doi:
10.1093/infdis/jiu396
PubMedGoogle ScholarCrossref 28.Joyner
MJ , Senefeld
JW , Klassen
SA ,
et al Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience.
medRxiv. Published online August 12, 2020:2020.08.12.20169359. doi:
10.1101/2020.08.12.20169359
Google Scholar 34.Rivera
DR , Peters
S , Panagiotou
OA ,
et al; COVID-19 and Cancer Consortium. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study.
Cancer Discov. 2020;10(10):1514-1527. doi:
10.1158/2159-8290.CD-20-0941
PubMedGoogle ScholarCrossref 36.Chari
A , Samur
MK , Martinez-Lopez
J ,
et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Blood. 2020;136(26):3033-3040. doi:
10.1182/blood.2020008150
PubMedGoogle ScholarCrossref 37.Hultcrantz
M , Richter
J , Rosenbaum
CA ,
et al COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers.
Blood Cancer Discov. 2020;1(3):234-243. doi:
10.1158/2643-3230.BCD-20-0102
Google ScholarCrossref